Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CONMED's BioBrace and AirSeal platforms, robotic growth and easing supply bottlenecks support its long-term outlook despite tariff headwinds.
Conmed (CNMD) Up 7.1% Since Last Earnings Report: Can It Continue?
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?
CNMD Jumps 16% in a Month as Investors Assess Whether It Can Last
CNMD's 16% monthly rally is backed by stronger growth, margin gains and raised earnings guidance, but cash-flow and execution risks remain.
Can CONMED's Raised 2026 EPS Outlook Reinforce Its Growth Momentum?
CONMED raised its 2026 adjusted EPS outlook after a strong second quarter, but slower organic growth and higher financing costs keep the setup mixed.
Is CNMD a Buy Now as Low Valuation Meets Persistent Execution Risk?
CNMD's low valuation and improved earnings outlook strengthen its appeal, but cash-flow pressure and execution risks keep the buy case measured.
Here's Why You Should Retain CONMED Stock in Your Portfolio Now
CONMED's growth outlook is supported by Buffalo Filter, BioBrace and organic momentum, though slower AirSeal growth and tariffs remain key risks.
CONMED Q2 Earnings and Revenues Beat Estimates, Gross Margin Expands
CNMD's Q2 earnings and revenues beat estimates, while margin growth and solid international sales support a higher 2026 EPS outlook.
CONMED Corporation (CNMD) Q2 2026 Earnings Call Transcript
CONMED Corporation (CNMD) Q2 2026 Earnings Call Transcript
CONMED Q2 Earnings Call Highlights
CONMED NYSE: CNMD reported second-quarter 2026 net sales of $343.5 million, up 0.3% on a reported basis but down 0.5% in constant currency. Organic sales, which exclude the company's exited gastroenterology product offerings, rose 6% year over year and modestly exceeded management's expectations.
Conmed (CNMD) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Conmed (CNMD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Conmed (CNMD) Q2 Earnings and Revenues Top Estimates
Conmed (CNMD) came out with quarterly earnings of $1.38 per share, beating the Zacks Consensus Estimate of $1.1 per share. This compares to earnings of $1.15 per share a year ago.
CONMED Expands AirSeal Robotic Solution for da Vinci 5 Hex Cannula
CNMD's FDA-expanded AirSeal indication adds da Vinci 5 hex cannula compatibility, supporting broader use across Intuitive Surgical's robotic systems.
